Benzinga | Jan 12, 2022 07:30AM EST

Vericel Sees FY21 Revenue Growth 25%-26%

In connection with its participation in the 40th Annual J.P. Morgan Healthcare conference on January 12, 2022, Vericel Corporation (the "Company") updated its corporate presentation to include disclosure that the Company estimates its full-year revenue growth for fiscal year 2021 to be in the range of 25%-26%, and its total adjusted EBITDA for the year to be approximately $30 million, based on preliminary unaudited financial results. The corporate presentation also includes disclosure that the Company had approximately $129 million in cash and investments as of December 31, 2021. The presentation further includes certain updates regarding the Company's life cycle management initiatives.